Conditions: Sarcoma
Keywords: high-risk soft tissue sarcoma pazopanib retroperitoneal soft tissue sarcoma visceral soft tissue sarcoma votrient
Allocation: RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 1
Healthy volunteers: no

Brief summary:
This trial compares pazopanib to placebo as maintenance treatment over 2 years in patients with retroperitoneal and visceral high-risk soft tissue sarcomas after multimodal treatment including prior neo- and/or adjuvant doxorubicin / ifosfamide chemotherapy with regional hyperthermia.

Detailed description:

Arms:
arm 1: 800mg, oral, 24 months arm 2: 800mg, oral, 24 months

Interventions: intervention 1: Pazopanib intervention 2: Placebo (for Pazopanib)
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: